Samsung Group in talks to buy U.S. drugmaker Biogen

Investing.com - Financial Markets Worldwide

Please try another search

EconomyDec 30, 2021 11:31AM ET

Samsung BioLogics says report on Biogen deal talks untrue© Reuters. FILE PHOTO: Employees of Samsung Group work at the company’s headquarters in Seoul April 22, 2008. REUTERS/Jo Yong-Hak

(Reuters) – Samsung (KS:) BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc (NASDAQ:).

Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.

Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was “not true,” without giving any more details.

Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.

Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics (OTC:) bought auto electronics maker Harman International Industries (D:) in an $8 billion deal.

Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.

In June, Biogen’s controversial Alzheimer’s drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel’s view that the company had not proven the treatment’s clinical benefits.

Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.

But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug’s high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.

Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.

Related Articles

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
My Husband Isn’t a Magician: Nigerian First Lady, Oluremi Tinubu, Unveils Inherited Burdens thumbnail

My Husband Isn’t a Magician: Nigerian First Lady, Oluremi Tinubu, Unveils Inherited Burdens

During her remarks at the interdenominational church service to commemorate Nigeria’s 63rd Independence Anniversary in Abuja, the First Lady, Oluremi Tinubu, emphasized that her husband, President Bola Tinubu, should not be seen as a magician.  She reiterated that his administration is dedicated to working diligently to address the challenges facing the country. Oluremi says the
Read More
Texas Senate passes $10B plan to develop gas power plants thumbnail

Texas Senate passes $10B plan to develop gas power plants

Dive Brief: The Texas Senate on Wednesday approved a package of energy reforms including a $10 billion “energy insurance program” that aims to shore up grid reliability through development of a fleet of new gas-fired power plants capable of providing 10,000 MW. SB 6 passed 22-9, but it faces broad opposition from the power sector
Read More
Trade.com Hires Michalis Tsaousellis as Chief Dealer thumbnail

Trade.com Hires Michalis Tsaousellis as Chief Dealer

Trade Capital Markets (TCM) Limited, the operator of forex and CFDs broker Trade.com, has hired Michalis Tsaousellis as the Chief Dealer. Based in Cyprus, he is responsible for managing the company’s trading team, developing and introducing new products, and optimizing the product development process. Further, he is overseeing and analyzing traded market risk activities.Trade.com Cyprus
Read More
‎NESR plans to IPO stake on Tadawul soon: executive director thumbnail

‎NESR plans to IPO stake on Tadawul soon: executive director

Tadawul screen National Energy Services Reunited Corp. (NESR) is planning to list a stake on the Saudi Exchange (Tadawul) soon, said Executive Director Naif Al-Hadrami. Speaking to CNBC Arabia, the top executive added that NESR is the first Saudi company to list shares on US markets and also the first to carry out a dual…
Read More
Index Of News
Total
0
Share